Toxic epidermal necrolysis in a patient on atorvastatin therapy expressing human leukocyte antigen alleles: A case report

• Published in: Medicine (Baltimore) Vol. 100; no. 3; p. e24392
• Main Authors: Lv, Meina, Jiang, Shaojun, Fu, Jinglan, Liu, Yuxin, Lian, Siheng, Zhang, Jinhua
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 22.01.2021
• Subjects: Aged; Alleles; Atorvastatin - adverse effects; Atorvastatin - therapeutic use; Clinical Case Report; Female; HLA Antigens - analysis; Humans; Stevens-Johnson Syndrome - drug therapy; Stevens-Johnson Syndrome - physiopathology
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000024392

Toxic epidermal necrolysis (TEN) is a rare, severe mucosal response of the skin associated with a high mortality rate. TEN is most commonly caused by drugs, and is characterized by extensive skin epidermal exfoliation. A 68-year-old woman presented with a rash that had persisted for four days. The patient who had undergone a mitral valve replacement 1 month prior and was taking atorvastatin at the time of admission. The patient exhibited more than 30% exfoliation surfaces and the severe drug eruption was considered to be TEN. According to human leukocyte antigen (HLA) allele detection and ALDEN score, HLA alleles which found in this case report may be an cause of TEN induced by atorvastatin. All drugs used prior to admission were discontinued and the patient was given antiallergic drugs. After 3 weeks following Antiallergic treatment, the rash on patient's calf had subsided, the edema was relieved, and the patient was no longer experiencing pain. After 60 days following discharge, the patient's skin has regrown. This is the first report describing the induction of TEN by atorvastatin in a HLA alleles carrier. For HLA alleles carrier, atorvastatin may need to be used with caution to avoid TEN. Future systematic research is also required to confirm this finding and avoid similar serious skin adverse reactions.